Expertise in
5
conditions

Emilie Del Tedesco

CHU Saint ÉTienne, Rhône Alpes
Saint-etienne-de-valoux, FR 
Expertise in
5
conditions
CHU Saint ÉTienne, Rhône Alpes
Saint-etienne-de-valoux, FR 

Overview

Emilie Del Tedesco practices practicing medicine in Saint-etienne-de-valoux, France.

Ms. Del Tedesco is highly rated in 5 conditions, according to our data. Her clinical expertise encompasses Viral Gastroenteritis, Colitis, Hemorrhagic Proctocolitis, Colonoscopy, and Endoscopy.

She is actively involved in clinical research, co-authoring 27 peer reviewed articles and participating in 10 clinical trials.

Gender

Female

Locations

CHU Saint Étienne, Rhône Alpes
Saint-etienne-de-valoux, France
Other Locations
Saint-priest-la-vetre, France
Saint Étienne, France
Paris, France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening, in First Degree Relatives of Patients With Colorectal Neoplasia: a Prospective Randomized Study.
Efficacy of Colonoscopy, Colon Capsule and Fecal Immunological Test for Colorectal Cancer Screening, in First Degree Relatives of Patients With Colorectal Neoplasia: a Prospective Randomized Study.
Enrollment Status: Completed
Publish Date: February 27, 2026
Intervention Type: Diagnostic test, Procedure
Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up
Detection of Herpesvirus DNA (CMV, EBV, HHV-6 and HSV) in Colonic Tissue: Impact on Ulcerative Colitis Flare-up
Enrollment Status: Terminated
Publish Date: June 05, 2025
Intervention Type: Biological, Procedure
Study Drug: Blood sample
Study Phase: Not Applicable
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Phase IIb Multicenter Randomized Comparative Study of Anti-pneumococcal Vaccine Strategy in Patients Treated With Immunosuppressants or Biotherapies for Chronic Inflammatory Bowel Disease
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Biological
Study Drugs: Prevenar 13, Pneumo 23
Study Phase: Phase 2
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
VEDO-PREDIRESP Project: Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Crohn's Disease
Enrollment Status: Terminated
Publish Date: June 15, 2023
Intervention Type: Drug
Study Drug: Vedolizumab
Study Phase: Phase 4
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Intensive Treatment to Reach the Target With Golimumab in ulcErative coliTis- In-TARGET
Enrollment Status: Completed
Publish Date: May 31, 2023
Intervention Type: Drug
Study Drug: Golimumab
Study Phase: Phase 4
Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis
Value of Pharmacokinetic Assays (Vedolizumab and Anti-vedolizumab Antibody) in the Prediction of Induction and Maintenance Therapeutic Response in Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: May 23, 2023
Intervention Type: Device, Procedure
Study Phase: Not Applicable
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Pharmacokinetic and Pharmacodynamic Study of Golimumab in Ulcerative Colitis (UC) Patients With Loss of Response (LOR) Followed by Dose Optimization
Enrollment Status: Completed
Publish Date: March 14, 2022
Intervention Type: Drug, Diagnostic test, Biological
Study Drug: Golimumab
Study Phase: Phase 2
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial.
Combination Corticosteroids+5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis: A Protocol of a Multi-center Prospective Randomized Investigator Blinded Trial.
Enrollment Status: Completed
Publish Date: August 26, 2021
Intervention Type: Drug
Study Drugs: 5-ASA, Corticosteroids
Study Phase: Phase 3
Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne.
Study of the Colonic Carriage of Staphylococcus Aureus in a Prospective Cohort of Patients Undergoing Endoscopic Screening for Digestive Cancer in the University Hospital of Saint-Etienne.
Enrollment Status: Completed
Publish Date: September 28, 2018
Intervention Type: Other
Study Phase: Not Applicable
Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial
Identification of Composite Clinical and Lab Scores Associated With a Favorable Clinical Response With Thiopurines in Patients With IBD (Inflammatory Bowel Disease): an International Clinical Trial
Enrollment Status: Completed
Publish Date: August 22, 2017
Intervention Type: Other
View 9 Less Clinical Trials

27 Total Publications

Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Addition of azathioprine to the switch of anti-TNF in patients with IBD in clinical relapse with undetectable anti-TNF trough levels and antidrug antibodies: a prospective randomised trial.
Journal: Gut
Published: August 30, 2019

Frequently Asked Questions about Emilie Del Tedesco

Is Emilie Del Tedesco a top-rated expert for Viral Gastroenteritis?

MediFind is an objective health platform that identifies experts based on real-world data. Emilie Del Tedesco is classified as an Distinguished expert for Viral Gastroenteritis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Emilie Del Tedesco participate in research or clinical trials?

Yes. Emilie Del Tedesco has published 27 articles and abstracts on conditions like Viral Gastroenteritis. You can view a list of Emilie Del Tedesco's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Del Tedesco's expertise for a condition
ConditionClose
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile